Brief: Magenta Therapeutics And Heidelberg Pharma Sign Agreement For Development Of Antibody Drug Conjugates

Heidelberg Pharma AG

05/03/2018 14:35

March 5 (Reuters) - Heidelberg Pharma Ag  WL6G.DE :
    * MAGENTA THERAPEUTICS AND HEIDELBERG PHARMA SIGN EXCLUSIVE
MULTI-TARGET RESEARCH AGREEMENT FOR THE DEVELOPMENT OF ANTIBODY
DRUG CONJUGATES
    * HEIDELBERG PHARMA AG - ‍MAGENTA WILL HAVE ACCESS TO CO'S
AMANITIN TOXIN-LINKER PLATFORM TECHNOLOGY​
    * HEIDELBERG PHARMA AG -MAGENTA HAS OPTION FOR EXCLUSIVE
TARGET-SPECIFIC LICENSE FOR GLOBAL DEVELOPMENT,
COMMERCIALIZATION RIGHTS TO PRODUCT CANDIDATES
    * HEIDELBERG PHARMA AG - ‍CO TO RECEIVE UPFRONT TECHNOLOGY
ACCESS,
EXCLUSIVITY FEES, PAYMENTS FOR RESEARCH SUPPORT​
    * HEIDELBERG PHARMA - TO BE ELIGIBLE TO RECEIVE OPTION FEES,
DEVELOPMENT, REGULATORY,SALES-RELATED MILESTONE PAYMENTS UP TO
$334 MILLION, UNDER CONDITIONS​

Source text for Eikon:  ID:nBwMwbHxa 
Further company coverage:  WL6G.DE 

 (Reuters.Briefs@thomsonreuters.com)